Incyte Corporation is a biotechnology business based in the US. Incyte Corporation shares (INCY) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $67.86 – a decrease of 4.14% over the previous week. Incyte Corporation employs 2,617 staff and has a trailing 12-month revenue of around $4.2 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $67.86 |
|---|---|
| 52-week range | $50.35 - $83.95 |
| 50-day moving average | $71.61 |
| 200-day moving average | $67.70 |
| Wall St. target price | $78.26 |
| PE ratio | 452.4 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.15 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $67.71 from 2025-03-13
| 1 week (2025-03-07) | -4.35% |
|---|---|
| 1 month (2025-02-14) | -3.85% |
| 3 months (2024-12-13) | -1.23% |
| 6 months (2024-09-13) | 6.53% |
| 1 year (2024-03-15) | 16.00% |
|---|---|
| 2 years (2023-03-15) | -6.57% |
| 3 years (2022-03-15) | 73.31 |
| 5 years (2020-03-13) | 73.84 |
Valuing Incyte Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Incyte Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Incyte Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 452x. In other words, Incyte Corporation shares trade at around 452x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Incyte Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4334. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Incyte Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Incyte Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $177.6 million.
The EBITDA is a measure of a Incyte Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4.2 billion |
|---|---|
| Operating margin TTM | 25.34% |
| Gross profit TTM | $1.5 billion |
| Return on assets TTM | 0.86% |
| Return on equity TTM | 0.75% |
| Profit margin | 0.77% |
| Book value | $17.82 |
| Market Capitalization | $13.1 billion |
TTM: trailing 12 months
We're not expecting Incyte Corporation to pay a dividend over the next 12 months.
Incyte Corporation's shares were split on a 2:1 basis on 31 August 2000 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Incyte Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Incyte Corporation shares which in turn could have impacted Incyte Corporation's share price.
Over the last 12 months, Incyte Corporation's shares have ranged in value from as little as $50.3498 up to $83.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Incyte Corporation's is 0.76. This would suggest that Incyte Corporation's shares are less volatile than average (for this exchange).
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Check out the best-performing ETFs so far in 2025.